Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
作者信息
Sommerstein Rami, Kochen Michael M, Messerli Franz H, Gräni Christoph
机构信息
Department of Infectious Diseases Bern University Hospital Bern Switzerland.
Institute of Family Medicine University of Freiburg Germany.
出版信息
J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
Abstract
摘要
相似文献
1
Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?2019冠状病毒病（COVID-19）：血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂是否具有双相效应？
J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
2
Drugs and the renin-angiotensin system in covid-19.新冠病毒肺炎中的药物与肾素-血管紧张素系统
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
3
COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.2019冠状病毒病与心血管疾病：我们已知的、我们自认为已知的以及我们需要了解的情况。
J Mol Cell Cardiol. 2020 Jul;144:12-14. doi: 10.1016/j.yjmcc.2020.04.026. Epub 2020 Apr 24.
4
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?新型冠状病毒肺炎与血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂：证据是什么？
JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
5
Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.2019冠状病毒病（COVID-19）：血管紧张素转换酶抑制剂、血管紧张素II受体阻滞剂与心血管疾病
Med J Aust. 2020 Jun;212(11):502-503.e1. doi: 10.5694/mja2.50622. Epub 2020 May 21.
6
Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety.COVID-19 患者的药物治疗：血管紧张素转换酶 2 升高药物及其临床安全性综述。
J Drug Target. 2020 Aug-Sep;28(7-8):683-699. doi: 10.1080/1061186X.2020.1797754. Epub 2020 Aug 12.
7
Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.SARS-CoV-2 与肾素血管紧张素系统相互作用的临床意义：美国心脏病学会评论专题周报。
J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095. doi: 10.1016/j.jacc.2020.04.028. Epub 2020 Apr 16.
8
The role of ACEIs/ARBs in COVID-19: Friend or foe?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂在2019冠状病毒病中的作用：是友还是敌？
Med Hypotheses. 2020 Sep;142:109810. doi: 10.1016/j.mehy.2020.109810. Epub 2020 May 5.
9
Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.血管紧张素转换酶2（ACE2）受体及血管紧张素转换酶抑制剂（ACEIs）/血管紧张素Ⅱ受体阻滞剂（ARBs）与新型冠状病毒肺炎（COVID-19）疾病严重程度的关联
Drug Discov Ther. 2020;14(4):161-170. doi: 10.5582/ddt.2020.03064.
引用本文的文献
1
Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection.血管紧张素转换酶抑制和/或血管紧张素受体阻断调节细胞因子谱并改善实验性 COVID-19 感染的临床结局。
Int J Mol Sci. 2025 Aug 8;26(16):7663. doi: 10.3390/ijms26167663.
2
Impact of Hypertension and Antihypertensive Treatment on COVID-19 Severity: A Retrospective Observational Study in Ternopil Region, Ukraine.高血压及降压治疗对新冠病毒疾病严重程度的影响：乌克兰捷尔诺波尔地区的一项回顾性观察研究
Ther Clin Risk Manag. 2025 Jun 25;21:995-1007. doi: 10.2147/TCRM.S527151. eCollection 2025.
3
Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19.在实验性新冠肺炎中，赖诺普利可提高肺部血管紧张素转换酶2（ACE2）水平和严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量，并减轻炎症，但不会降低疾病严重程度。
Front Pharmacol. 2024 Jul 12;15:1414406. doi: 10.3389/fphar.2024.1414406. eCollection 2024.
4
The renin-angiotensin-aldosterone system inhibitor dilemma in COVID-19: balancing cardiovascular benefits and viral risks.新型冠状病毒肺炎中肾素-血管紧张素-醛固酮系统抑制剂的困境：权衡心血管益处与病毒风险
Hypertens Res. 2024 Sep;47(9):2598-2600. doi: 10.1038/s41440-024-01772-x. Epub 2024 Jul 1.
5
Pathogenic mechanisms of cardiovascular damage in COVID-19.COVID-19 中心血管损伤的发病机制。
Mol Med. 2024 Jun 19;30(1):92. doi: 10.1186/s10020-024-00855-2.
6
The Epidemiology of COVID-19 Vaccine-Induced Myocarditis.新型冠状病毒肺炎疫苗诱导的心肌炎的流行病学
Adv Med. 2024 Apr 18;2024:4470326. doi: 10.1155/2024/4470326. eCollection 2024.
7
COVID-19 and cardiovascular comorbidities: An update.新型冠状病毒肺炎与心血管合并症：最新进展
Rev Port Cardiol (Engl Ed). 2020 Aug;39(8):417-419. doi: 10.1016/j.repce.2020.06.002. Epub 2020 Dec 16.
8
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
9
Clinical Outcomes of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in COVID-19 Patients With Pre-existing Cardiac Comorbidities: A Literature Review.血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂在合并心脏基础疾病的COVID-19患者中的临床结局：一项文献综述
Cureus. 2023 Dec 28;15(12):e51244. doi: 10.7759/cureus.51244. eCollection 2023 Dec.
10
COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigation.血脂异常对新冠病毒病易感性和严重程度的影响：孟德尔随机化研究
Heliyon. 2023 Sep 16;9(9):e20247. doi: 10.1016/j.heliyon.2023.e20247. eCollection 2023 Sep.
本文引用的文献
1
The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020.2019新型冠状病毒病（COVID-19）疫情的流行病学特征 - 中国，2020年
China CDC Wkly. 2020 Feb 21;2(8):113-122.
2
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.美国心力衰竭学会/美国心脏病学会/美国心脏协会联合声明回应关于在2019冠状病毒病中使用肾素-血管紧张素-醛固酮系统拮抗剂的担忧。
J Card Fail. 2020 May;26(5):370. doi: 10.1016/j.cardfail.2020.04.013.
3
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.2019冠状病毒病（COVID-19）与心血管疾病：关于血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的发病和严重程度潜在影响的观点
J Am Heart Assoc. 2020 Apr 7;9(7):e016219. doi: 10.1161/JAHA.120.016219. Epub 2020 Apr 1.
4
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
5
Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016.2005 - 2016年美国成年人抗高血压药物单一疗法和联合使用趋势，美国国家健康与营养检查调查
Hypertension. 2020 Apr;75(4):973-981. doi: 10.1161/HYPERTENSIONAHA.119.14360. Epub 2020 Mar 9.
6
An interactive web-based dashboard to track COVID-19 in real time.一个基于网络的交互式仪表盘，用于实时追踪新冠病毒。
Lancet Infect Dis. 2020 May;20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1. Epub 2020 Feb 19.
7
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
8
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
9
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
10
Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?血管紧张素转换酶抑制剂在高血压中的应用：用还是不用？
J Am Coll Cardiol. 2018 Apr 3;71(13):1474-1482. doi: 10.1016/j.jacc.2018.01.058.
Zotero 插件